flanders.bio is an independent life sciences cluster organisation based in Flanders, Belgium

flanders.bio is a dynamic, member driven organisation with currently more than 350 members from Belgium and abroad. We help our members to create value by organising Networking and Training Activities, supporting Internationalisation, providing Services and building Expertise. flanders.bio and its members want to be the proud advocates of a reputable global-impact ecosystem in life sciences.

News from flanders.bio and its members

OCTIMET Oncology announces the appointment of Shelley Margetson as CEO

OCTIMET Oncology, a clinical-stage biotech company with a focus on the development of highly specific and differentiated oral kinase inhibitors, announces the appointment of Shelley Margetson as CEO. Timothy Perera PhD, founder of the company, will continue as CSO.

Idylla(TM) MSI Performance Study Selected for Publication at ASCO Conference

Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that a multi-centered[1] study on the performance of the Idylla(TM) MSI Test (CE IVD) in comparison with the Promega MSI test[2] ('Promega MSI Test') has been selected for publication at the renowned ASCO (American Society of Clinical Oncology) Annual Meeting. The study showed high performance and a low invalid rate of the Idylla(TM) MSI Test, as such demonstrating the possibility of rapid, fully automated MSI testing with Idylla(TM). The ASCO conference takes place between 30 May and 4 June 2019 in Chicago (IL), US.

Brain imaging AI leader icometrix raises $18 million in new funding

Leuven/Geneva/Boston icometrix, the global expert in brain imaging Artificial Intelligence solutions, has raised $18 million through a partnership led by Forestay Capital alongside Optum Ventures and existing investor Capricorn Venture Partners.

Preventing cell death as novel therapeutic strategy for rheumatoid arthritis

A collaborative study by research groups from the University of Cologne, VIB, Ghent University, the Βiomedical Sciences Research Center ‘Alexander Fleming’ in Athens and the University of Tokyo identified a new molecular mechanism causing rheumatoid arthritis. The researchers found that death of macrophages, an immune cell type, can trigger the disease. Moreover, they discovered how the protein A20 prevents macrophage death and protects against arthritis. These findings open up new possibilities for the treatment of this debilitating disease.

flanders.bio events, trainings & international missions

Strategic Partners